How I treat splenomegaly in myelofibrosis.

about

Practical management of patients with myelofibrosis receiving ruxolitinib.Managing patients with myelofibrosis and low platelet counts.Definition and management of ruxolitinib treatment failure in myelofibrosis.

P2860

Q33410649-72223507-00FA-44E7-9400-5F4C2F9E1744 Q33432406-54A84BE2-01D1-43F1-A851-8F84C1902451 Q38287012-C9D456E7-2CEF-4BC2-A3E2-4E61F736DD0E

P2860

How I treat splenomegaly in myelofibrosis.

Item

http://www.wikidata.org/entity/Q39244371

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

How I treat splenomegaly in myelofibrosis.

@en

How I treat splenomegaly in myelofibrosis.

@nl

type

Item

label

How I treat splenomegaly in myelofibrosis.

@en

How I treat splenomegaly in myelofibrosis.

@nl

prefLabel

How I treat splenomegaly in myelofibrosis.

@en

How I treat splenomegaly in myelofibrosis.

@nl

P1476

How I treat splenomegaly in myelofibrosis.

@en

P2093

F Cervantes

http://www.w3.org/2001/XMLSchema#string

P2860

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Modern management of myelofibrosis.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

P2888

bcj.2011.36

P304

e37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2011.36

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565349

http://www.w3.org/2001/XMLSchema#string

P6179

1048196066

http://www.w3.org/2001/XMLSchema#string

P698

22829071

http://www.w3.org/2001/XMLSchema#string

P932

3255257

http://www.w3.org/2001/XMLSchema#string

How I treat splenomegaly in myelofibrosis.

about

P2860

P2860

How I treat splenomegaly in myelofibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932